NewEdge Advisors’s Niagen Bioscience NAGE Stock Holding History

NewEdge Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-19,779	Closed	-$126K	–	4446
2025 Q4	$126K	Sell	19,779 -2,206	-10%	-$15.3K	﹤0.01%	2696
2025 Q3	$205K	Buy	21,985 +2,261	+11%	+$22.8K	﹤0.01%	2403
2025 Q2	$284K	Sell	19,724 -8,012	-29%	-$79.1K	﹤0.01%	2050
2025 Q1	$191K	Buy	27,736 +25,563	+1,176%	+$161K	﹤0.01%	2110
2024 Q4	$11.5K	Sell	2,173 -11,196	-84%	-$61.3K	﹤0.01%	2991
2024 Q3	$48.8K	Buy	+13,369	New	+$42.1K	﹤0.01%	2440
2024 Q2	–	Sell	-21,415	Closed	-$74.5K	–	4033
2024 Q1	$74.5K	Buy	+21,415	New	+$39.6K	﹤0.01%	2162

Other funds holding NAGE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NewEdge Advisors's NAGE Position: Q1 2026 in Review

NewEdge Advisors sold out of Niagen Bioscience (NAGE) in Q1 2026, closing a stake of 19,779 shares — an estimated $126K sold.

NewEdge Advisors first reported a position in NAGE in Q1 2024 and held it in 7 quarters. The position peaked at $284K in Q2 2025. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.

NewEdge Advisors reported no remaining Niagen Bioscience position as of Q1 2026 after selling out during the quarter.
NewEdge Advisors sold 19,779 Niagen Bioscience shares in Q1 2026, an estimated $126K.
NewEdge Advisors first reported a position in Niagen Bioscience in Q1 2024 and held it in 7 quarters.
NewEdge Advisors's Niagen Bioscience position peaked at $284K in Q2 2025.
143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.